Literature DB >> 24129221

Escitalopram-associated acute urinary retention.

Dominick Trombetta1, Kathleen Garrett, Marissa Harrison.   

Abstract

New-onset urinary retention can typically be explained by the use of the routine normally suspected medications (e.g., anticholinergics, antihistamines). However, selective serotonin-reuptake inhibitors are not typically presumed as the cause of acute urinary retention (AUR). The following case describes the introduction of escitalopram in a patient and the subsequent development of AUR. Medical causes of urinary retention had been ruled out, and ipratropium was initially suspected to be the cause of urinary difficulties and was discontinued. However, the retention persisted four days after suspending the ipratropium. Normal micturition resumed only after stopping the escitalopram without further need for catheterization. Escitalopram may cause rare cases of AUR and may often times be overlooked possibly because of the paucity of reporting.

Entities:  

Keywords:  5-HT = 5-hydroxytryptophan; AUR = Acute urinary retention; Acute urinary retention; Anticholinergics; Antihistamines; CYP = Cytochrome; Escitalopram; INR = International normalized ratio; M1 = Muscarinic-1 receptor; MDI = Metered-dose inhaler; PVR = Postvoid residuals; SSRI = Selective serotonin-reuptake inhibitor; Selective serotonin reuptake inhibitors; UTI = Urinary tract infection; Urinary retention

Mesh:

Substances:

Year:  2013        PMID: 24129221     DOI: 10.4140/TCP.n.2013.661

Source DB:  PubMed          Journal:  Consult Pharm        ISSN: 0888-5109


  2 in total

1.  Bladder dysfunction in presymptomatic gene carriers and patients with Huntington's disease.

Authors:  Matej Kolenc; Metka Moharić; Jan Kobal; Simon Podnar
Journal:  J Neurol       Date:  2014-09-20       Impact factor: 4.849

2.  Polypharmacy and adverse outcomes after hip fracture surgery.

Authors:  Maria Härstedt; Cecilia Rogmark; Richard Sutton; Olle Melander; Artur Fedorowski
Journal:  J Orthop Surg Res       Date:  2016-11-24       Impact factor: 2.359

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.